Eli Lilly reported a 35 percent rise in quarterly profit as the U.S. drugmaker benefited from higher sales of its diabetes treatment Trulicity as well as its psoriasis drug Taltz.
Continue Reading Below
Net income rose to $1.01 billion, or 95 cents per share, in the second quarter ended June 30, from $747.7 million, or 71 cents per share, a year earlier.
Revenue rose to $5.82 billion from $5.40 billion.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Martina D'Couto)